Everolimus (RAD001) 化学構造
分子量: 958.22

品質と確認

カスタマーレビュー(1)

Quality Control & MSDS

製品情報

製品の説明

生物活性

情報 Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。
目標 mTOR (FKBP12)
IC50 1.6-2.4 nM [1]
In vitro試験 Everolimus exhibits the immunosuppressive activity which is comparable to that of rapamycin. Everolimus competes with immobilized FK 506 for binding to biotinylated FKBP12 and shows the inhibitory effect on a two-way MLR performed with spleen cells from BALB/c and CBA mice with IC50 of 0.12-1.8 nM. [1] Everolimus also shows antiangiogenic/vascular effects in VEGF-induced HUVEC proliferation with IC50 of 0.12 nM and bFGF-induced HUVEC proliferation with IC50 of 0.8 nM, respectively. [2] A recent study shows that Everolimus shows a dose-dependent inhibitory effects on both the total cells and the stem cells from the BT474 cell line and the primary breast cancer cells with IC50 of 156 nM in total cells of primary breast cancer cells and 71 nM in total cells of BT474 cells. In addition, combination treatment with Everolimus and trastuzumab produces the significantly increased inhibition on the growth of cancer stem cells with the inhibition rate increased by more than 50 %. [3]
In vivo試験 Everolimus (0.1 to 10 mg/kg) dose-dependently inhibits growth of the primary (ear) and lymph node metastases of B16/BL6 melanoma, with decreased total number of vessels and reduced mature vessels. [2] In a xenograft animal model of BT474 stem cells, Everolimus shows significant reductions in mean tumor sizes (590.6 mm3), compared to the control group with a tumor size of 698 mm3. Furthermore, combination treatment with Everolimus and trastuzumab significantly decreases the xenograft tumor size (410.8 mm3) more than Everolimus treatment alone. [3]
臨床試験 Everolimus is currently in Phase I clinical trials in patients with Unspecified Adult Solid Tumor.
特集

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

FKBP12 binding assay & Mixed lymphocyte reaction (MLR) FKBP12 binding assay: Binding to the FK 506 binding protein (FKBP12) is indirectly assessed by means of an ELISA-type competition assay. FK 506 is included in each individual experiment as a standard, and the inhibitory activity is expressed as relative IC50 compared to FK 506 (rIC50 = IC50 Everolimus/IC50 FK 506). Mixed lymphocyte reaction (MLR): The immunosuppressive activities of RAP and its derivatives are assessed in a two-way MLR, using spleen cells of BALB/c and CBA mice. RAP is included in each individual experiment as a standard, and the inhibitory activity is expressed as relative IC50 compared to RAP (rIC50 = IC50 Everolimus/IC50 RAP).

細胞アッセイ: [3]

細胞系 BT474 cell line and the primary breast cancer cells
濃度 0.001-10 μM
処理時間 24 hours
方法 The 3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye reduction assay (MTT assay) is used to compare the effects of Everolimus or trastuzumab on total breast cancer cells and breast CSCs. The total cells and the stem cells from the BT474 cell line and the primary breast cancer cells are respectively seeded into 96-well plates with different concentrations of the drugs, with five wells for each concentration, and the cells are cultured at 37 °C with 5 % CO2 in an incubator for 24 hours. The concentrations of Everolimus are 1 nM, 10 nM, 100 nM, 1 μM and 10 μM, and the concentrations of trastuzumab are 0.5 μg/mL, 1 μg/mL, 10 μg/mL, 50 μg/mL, and 100 μg/mL. The combinatorial inhibitory effect of Everolimus and Trastuzumab on the in vitro growth of breast CSCs is examined by MTT assay as well using 10 μg/mL trastuzumab in combination of increasing concentrations of everolimus (1 nM, 10 nM, 100 nM and 1 μM). After drug treatment for 24 hours, 20 μL MTT [5 mg/mL in phosphate buffered saline (PBS)] is added to each well, and the cells are incubated at 37 °C with 5 % CO2 and saturated humidity for 4 hours. Following the subsequent removal of the supernatant, 150 μL dimethyl sulfoxide (DMSO) is added to each well, and the cells are vortexed for 10 minutes. The light absorbance (OD value) is measured for each well using an ELISA reader. Each experiment is repeated in triplicate, and dose–response curves are plotted. The probit software of the statistical software package SPSS 17.0 for Windows is used to calculate the inhibitory concentration (IC50) of Everolimus.

動物実験: [3]

動物モデル Cultured BT474 stem cells are injected beneath the left breast pad of BALB/c nude mice.
製剤 Everolimus is dissolved in saline.
投薬量 ≤2 mg/kg
管理 Administered via p.o.
1

参考

化学情報

Download Everolimus (RAD001) SDF
分子量 958.22
化学式

C53H83NO14

CAS No. 159351-69-6
別名 Certican, Zortress, Afinitor
溶解度 (25°C)
  • DMSO 30 mg/mL
  • 水 <1 mg/mL
  • エタノール 7 mg/mL
保管 2年 -20°C
6月-80°Cin DMSO
化学名 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine, rapamycin deriv

研究分野

カスタマーレビュー (1)


Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 216-226. Everolimus (RAD001) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 5 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

製品表彰状 (14)

  • NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. [Ying H, et al. Cell 2012;149(3):656-70]

    PubMed: 22920938
  • An animal model of MYC-driven medulloblastoma. [Pei Y, Moore CE, et al. Cancer Cell 2012;21(2):155-67]

    PubMed: 22340590
  • The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition. [Jiang X, et al. Clin Cancer Res 2013;19(3):598-609]

    PubMed: 23095323
  • Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. [Endo M, et al. Clin Cancer Res 2012;19(2):450-61]

    PubMed: 23209032
  • Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells [Ajabnoor GM, et al. Cell Death Dis 2012;3:e260]

    PubMed: 22278287
  • Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells. [Zeng JY, et al. Mol Cancer Ther 2013;13(1):37-48]

    PubMed: 24233399
  • Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. [Tap WD, et al. Neoplasia 2010;12(8):637-49]

    PubMed: 20689758
  • Automated image analysis of nuclear shape: What can we learn from a prematurely aged cell? [Driscoll MK, et al. Aging (Albany NY) 2012;4(2):119-32]

    PubMed: 22354768
  • Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression. [Kim YS, et al. Bioch Pharm 2011;82(3):216-26]

    PubMed: 21601561
  • Benzofuran derivatives as a novel class of inhibitors of mTOR signaling [Christophe Salom? et al. European Journal of Medicinal Chemistry 2013;10.1016/j.ejmech.2013.12.020]

  • Heregulin induces resistance to lapatinib-mediated growth inhibition of HER4-amplified cancer cells. [Sato Y, et al. Cancer Sci 2013;104(12):1618-25]

    PubMed: 24112719
  • Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor. [Yang F, et al. Cancer Biol Ther 2012;13(6):349-57]

    PubMed: 22313636
  • The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. [Li Q, et al. Biochem Biophys Res Commun 2013;440(4):701-6]

    PubMed: 24103749
  • Evidence for the existence of triple-negative variants in the MCF-7 breast cancer cell population [Euphemia Leung. University of Auckland 2013;Euphemia Leung]

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related mTOR 阻害剤

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)は競争性的なPI3K、mTOR 阻害剤、 p110α, p110γ, p110δ と p110β を作用すると、 IC50 がぞれぞれ 4 nM, 5 nM, 7 nM と 75 nMになる.

  • Ridaforolimus (Deforolimus, MK-8669)

    Ridaforolimus (Deforolimus, MK-8669) は、0.2nMのIC50による選択的なmTOR阻害剤です。

  • PI-103

    PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • KU-0063794

    KU-0063794は、IC50が10nMについてにあるmTORC1とmTORC2のための強力で非常に特定のmTOR阻害剤です。

  • WYE-354

    WYE-354は、mTORへの強力で、特定で、ATP競争的阻害剤で 、IC50 が 5 nMになる。

  • GSK1059615

    GSK1059615は、ホスホイノシチド3-キナーゼ(PI3Kα、β、δとγ)とラパマイシン(mTOR)の哺乳類の標的の小説と二重阻害剤で 、IC50 が 0.4-12 nMになる。

  • SAR245409 (XL765)

    SAR245409 (XL765)は、mTOR/PI3kの二重阻害剤で、mTOR、 p110α、 p110β、 p110γ 、p110δに作用すると、 IC50 がそれぞれ 157 nM、39 nM、 113 nM、 9 nM 、43 nMになる。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

最近見られたアイテム

Tags: Everolimus (RAD001)を買う | Everolimus (RAD001)供給者 | Everolimus (RAD001)を購入する | Everolimus (RAD001)費用 | Everolimus (RAD001)生産者 | オーダーEverolimus (RAD001) | Everolimus (RAD001)代理店
お問い合わせ